Recent Finacing
Recent Raise
Cempra Pharmaceuticals develops macrolide-based antibiotics for drug-resistant bacteria, advancing TAKSTA toward phase 3 for skin/MRSA infections and solithromycin into phase 2 for community-acquired pneumonia, maintaining a ~500-compound macrolide library.
Focus Areas
Total Raised
Funding round